Welcome to our dedicated page for Amphastar Pharma SEC filings (Ticker: AMPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amphastar Pharmaceuticals filings document the regulatory disclosures of a Delaware biopharmaceutical company focused on generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredient products. Form 8-K reports furnish operating results, product revenue commentary, non-GAAP measures, and material business updates tied to the company's pharmaceutical products business.
Amphastar's SEC filings also cover governance and capital-structure matters, including proxy disclosures, executive compensation, employment agreements, equity-compensation dilution, and share repurchase authorizations. Material agreement filings describe licensing rights for a corticotropin compound, supply arrangements involving a Chinese subsidiary, related-party review procedures, and commercial terms that affect the company's pipeline, manufacturing, and distribution activities.
Amphastar Pharmaceuticals, Inc. (AMPH) reported an insider transaction by a director involving company common stock. On 11/13/2025, the director exercised a stock option for 16,679 shares of common stock at an exercise price of $16.69 per share and acquired those shares. On the same date, the director sold 16,679 shares of common stock at a weighted average price of $26.4906 per share, with individual sale prices ranging from $26.43 to $26.57. After these transactions, the director beneficially owned 75,531 shares of Amphastar common stock directly. The stock option covering 16,679 shares, which was fully vested and immediately exercisable and had an expiration date of 06/07/2026, now shows 0 derivative securities remaining beneficially owned.
Amphastar Pharmaceuticals reported Q3 2025 results. Net revenues were $191,840 thousand, with gross profit of $98,646 thousand and income from operations of $25,320 thousand. Net income was $17,350 thousand, or diluted EPS of $0.37.
Year to date, net revenues totaled $536,782 thousand and net income was $73,665 thousand. Q3 product mix included BAQSIMI at $53,608 thousand, Primatene MIST at $28,808 thousand, Lidocaine at $12,932 thousand, Epinephrine at $18,789 thousand, Glucagon at $13,558 thousand, and other products at $64,145 thousand.
Cash and cash equivalents were $216,265 thousand, short‑term investments $59,944 thousand, and inventories $185,932 thousand as of September 30, 2025. Total assets were $1,666,222 thousand. Long‑term debt (including the 2.00% 2029 convertible notes and a term loan) totaled $619,798 thousand, with long‑term debt, net of issuance costs and current portion, at $608,582 thousand. Operating cash flow for the nine months was $123,252 thousand. The company repurchased $55,070 thousand of shares year to date; treasury stock stood at $(387,653) thousand. Common shares outstanding were 45,952,174 as of October 31, 2025.
Amphastar Pharmaceuticals filed an 8-K stating it issued a press release announcing financial results for the three months ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The company notes the furnished information is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically referenced.
Amphastar Pharmaceuticals (AMPH): director sale reported. On 11/03/2025, a director sold 500 shares of common stock at a weighted average price of $25.2662 under a Rule 10b5-1 trading plan adopted on November 26, 2024. The trades occurred at prices ranging from $25.00 to $25.47. After this transaction, the reporting person beneficially owns 75,531 shares, held directly.
Amphastar Pharmaceuticals entered a Distribution Agreement effective October 21, 2025 with Nanjing Chengong Pharmaceutical to expand sales of BAQSIMI nasal powder across Mainland China, Taiwan, Hong Kong, and Macau. Amphastar appointed Chengong as the exclusive distributor in the Greater China region. Chengong will obtain regulatory approvals and conduct required post‑marketing clinical trials.
The agreement includes minimum purchase amounts per contract year and a profit‑sharing structure on earnings above a floor price per unit, determined using Chengong’s per‑unit net revenue. The term is 10 years, with both parties holding termination rights without cause after the fourth Contract Year. Payments will be in U.S. dollars, and total revenue over the term is not determinable based on the filing. The transaction is a related party arrangement: executives and certain family members beneficially own a majority of Hanxin, Chengong’s parent. The Company’s independent and disinterested Audit Committee members evaluated and approved the agreement.
Floyd F. Petersen, a director of Amphastar Pharmaceuticals, Inc. (AMPH), sold 500 shares of the company's common stock on 10/01/2025 at a weighted-average price of $27.2048 per share. The sale was made under a pre-established Rule 10b5-1 trading plan adopted on 11/26/2024. After the reported sale, Mr. Petersen beneficially owned 76,031 shares, held directly. The Form 4 was signed on behalf of the reporting person by Eva Wen as power of attorney on 10/02/2025. The registrant will provide, upon request, details on the number of shares sold at each execution price within the reported range of $26.74 to $27.39.
Insider sale notice for AMPH: This Form 144 shows a proposed sale of 500 shares of Amphastar Pharmaceuticals common stock through UBS Financial Services on or about 10/01/2025, with an aggregate market value listed as $13,370.00. The shares were originally acquired as RSUs on 06/07/2022. The filer previously sold three blocks of 500 shares each during July, August and September 2025, generating gross proceeds of $11,733.95, $10,415.75, and $15,491.65 respectively. The filing lists total shares outstanding as 46,495,077, indicating the planned sale is a small fraction of the company’s outstanding shares. The notice includes the signer’s representation that no undisclosed material adverse information about the issuer is known.
Amphastar Pharmaceuticals entered into a three-year contract research agreement with Nanjing Hanxin Pharmaceutical Technology effective September 15, 2025. Under this deal, Hanxin will develop Recombinant Peptide Research Cell Banks (RCBs) for Amphastar’s product candidate AMP-107 and license them under a fully paid, exclusive, perpetual, transferable, sub-licensable worldwide license.
All title to the RCBs and related development and manufacturing know-how, including engineering, scientific data, designs, and procedures, will belong to Amphastar. The total cost of the agreement will not exceed approximately $2.8 million, paid in Chinese yuan, including an initial payment of about $0.3 million on the effective date, with any extra work billed on a cost-plus basis subject to prior approval.
The filing notes this is a related-party transaction because Amphastar CEO Dr. Jack Zhang, COO and Chairman Dr. Mary Luo, and certain family members beneficially own a majority of Hanxin’s equity. The independent and disinterested members of the Audit Committee evaluated and approved Amphastar’s entry into the agreement.
Amphastar Pharmaceuticals entered into a three-year contract research agreement with Nanjing Hanxin Pharmaceutical Technology effective September 15, 2025. Under this deal, Hanxin will develop Recombinant Peptide Research Cell Banks (RCBs) for Amphastar’s product candidate AMP-107 and license them under a fully paid, exclusive, perpetual, transferable, sub-licensable worldwide license.
All title to the RCBs and related development and manufacturing know-how, including engineering, scientific data, designs, and procedures, will belong to Amphastar. The total cost of the agreement will not exceed approximately $2.8 million, paid in Chinese yuan, including an initial payment of about $0.3 million on the effective date, with any extra work billed on a cost-plus basis subject to prior approval.
The filing notes this is a related-party transaction because Amphastar CEO Dr. Jack Zhang, COO and Chairman Dr. Mary Luo, and certain family members beneficially own a majority of Hanxin’s equity. The independent and disinterested members of the Audit Committee evaluated and approved Amphastar’s entry into the agreement.
Floyd F. Petersen, a director of Amphastar Pharmaceuticals (AMPH), sold 500 shares on 09/02/2025 under a pre-existing Rule 10b5-1 trading plan. The sales were executed at a weighted-average price of $30.9833 per share, with individual sale prices ranging from $30.60 to $31.225. Following the reported disposition, Petersen is recorded as beneficially owning 76,531 shares. The Form 4 was signed by Eva Wen by power of attorney on 09/03/2025.
Form 144 notice by Floyd Peterson for Amphastar Pharmaceuticals, Inc. (AMPH). The filer notifies a proposed sale of 500 shares of common stock through UBS Financial Services on NASDAQ with an approximate sale date of 09/02/2025 and an aggregate market value listed at $15,450.00. The shares were acquired as RSUs on 06/07/2022. The filing also discloses three sales by the same person in the past three months totaling 1,500 shares on 06/02/2025, 07/02/2025 and 08/01/2025 with combined gross proceeds of $34,984.75. The form includes the required representation that the seller is not aware of undisclosed material adverse information.